| Dec'14 | Sep'14 | Jun'14 | Mar'14 | Dec'13 | Sep'13 | Jun'13 | Mar'13 | Dec'12 | Sep'12 | Jun'12 | Mar'12 | Dec'11 | Sep'11 | Jun'11 | Mar'11 | Dec'10 | Sep'10 | Jun'10 | Mar'10 | Dec'09 | Sep'09 | Jun'09 | Mar'09 | Sep'08 | Jun'08 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||||||||||||||||||
Product net sales | |||||||||||||||||||||||||
1,889,000 | 1,790,700 | 1,827,300 | 1,619,100 | 1,659,600 | 1,528,400 | 1,577,000 | 1,432,500 | 1,447,800 | 1,353,700 | 1,426,100 | 1,321,700 | 1,179,700 | 1,311,100 | 1,400,400 | 1,252,800 | 1,290,100 | 1,192,000 | 1,231,700 | 1,105,800 | 1,206,500 | 1,127,800 | 1,118,700 | 994,600 | 1,081,900 | 1,155,800 |
Other revenues | |||||||||||||||||||||||||
21,500 | 26,400 | 36,900 | 27,000 | 24,800 | 30,300 | 20,700 | 27,100 | 24,300 | 22,800 | 24,000 | 26,200 | 19,500 | 17,300 | 16,800 | 18,400 | 19,200 | 16,200 | 15,500 | 48,900 | 17,800 | 13,500 | 12,100 | 12,600 | 16,300 | 16,200 |
Total revenues | |||||||||||||||||||||||||
1,910,500 | 1,817,100 | 1,864,200 | 1,646,100 | 1,684,400 | 1,558,700 | 1,597,700 | 1,459,600 | 1,472,100 | 1,376,500 | 1,450,100 | 1,347,900 | 1,199,200 | 1,328,400 | 1,417,200 | 1,271,200 | 1,309,300 | 1,208,200 | 1,247,200 | 1,154,700 | 1,224,300 | 1,141,300 | 1,130,800 | 1,007,200 | 1,098,200 | 1,172,000 |
Operating costs and expenses: | |||||||||||||||||||||||||
Cost of sales (excludes amortization of intangible assets) | |||||||||||||||||||||||||
209,100 | 206,600 | 222,200 | 204,500 | 204,600 | 192,200 | 199,100 | 199,900 | 183,000 | 182,900 | 195,300 | 190,000 | 151,300 | 188,100 | 195,300 | 183,300 | 182,800 | 177,700 | 191,300 | 170,200 | 184,600 | 190,200 | 198,300 | 177,800 | 194,700 | 197,500 |
Selling, general and administrative | |||||||||||||||||||||||||
745,000 | 714,700 | 718,900 | 658,600 | 715,400 | 589,300 | 609,900 | 604,800 | 542,300 | 522,900 | 563,100 | 564,800 | 463,600 | 538,500 | 566,700 | 589,500 | 527,500 | 517,300 | 499,000 | 473,800 | 497,600 | 497,500 | 441,900 | 484,500 | 440,400 | 506,900 |
Research and development | |||||||||||||||||||||||||
265,400 | 288,500 | 288,700 | 349,000 | 269,400 | 257,600 | 266,500 | 248,800 | 239,800 | 289,800 | 227,700 | 220,000 | 195,100 | 221,300 | 257,400 | 197,700 | 200,300 | 194,000 | 187,600 | 222,700 | 185,400 | 176,900 | 161,600 | 182,100 | 186,600 | 213,400 |
Amortization of intangible assets | |||||||||||||||||||||||||
27,600 | 29,000 | 28,000 | 27,800 | 28,200 | 28,800 | 29,000 | 30,700 | 23,000 | 22,800 | 23,100 | 21,300 | -9,500 | 31,900 | 31,200 | 32,500 | 32,500 | 31,100 | 37,300 | 37,100 | 36,200 | 36,000 | 35,500 | 38,600 | 39,300 | 35,800 |
Legal settlement | |||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 609,900 | - | - | - | 0 | - | - | - | - |
Impairment of intangible assets and related costs | |||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | -16,100 | 4,300 | 3,300 | 16,100 | 0 | 369,100 | 0 | 0 | - | 0 | - | - | - | - |
Restructuring charges | |||||||||||||||||||||||||
36,700 | 185,500 | -1,500 | 24,300 | 600 | 600 | 0 | 4,300 | 0 | 600 | 900 | 0 | -4,700 | -100 | 100 | 4,600 | -500 | 100 | 100 | 600 | 3,600 | 4,200 | 1,000 | 42,100 | -200 | 9,400 |
Operating income | |||||||||||||||||||||||||
626,700 | 392,800 | 607,900 | 381,900 | 454,800 | 490,200 | 493,200 | 371,100 | 461,700 | 357,500 | 440,000 | 351,800 | 419,500 | 344,400 | 363,200 | 247,500 | 367,400 | -691,000 | 331,900 | 250,300 | 316,900 | 236,500 | 292,500 | 82,100 | 237,400 | 209,000 |
Non-operating income (expense): | |||||||||||||||||||||||||
Interest income | |||||||||||||||||||||||||
1,500 | 2,000 | 2,400 | 1,800 | 1,700 | 1,500 | 2,000 | 1,600 | 1,900 | 1,900 | 1,700 | 1,200 | 1,300 | 1,800 | 1,500 | 2,300 | 3,200 | 1,600 | 1,200 | 1,300 | 1,400 | 1,400 | 1,500 | 2,700 | 6,500 | 10,300 |
Interest expense | |||||||||||||||||||||||||
15,600 | 18,400 | 19,700 | 15,700 | 18,200 | 19,400 | 20,000 | 17,400 | 14,800 | 15,900 | 17,100 | 15,800 | 16,700 | 15,200 | 15,200 | 24,700 | 27,800 | 20,400 | 13,900 | 16,600 | 21,200 | 17,800 | 18,500 | 19,400 | 20,800 | 21,000 |
Gain on investments, net | |||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 24,600 | - | - | 0 | - |
Unrealized (loss) gain on derivative instruments, net | |||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7,900 | -200 |
Other, net | |||||||||||||||||||||||||
21,300 | 43,000 | -16,200 | -6,400 | 2,700 | -15,500 | 11,200 | -8,700 | -3,800 | -9,200 | 4,900 | -15,000 | -10,900 | 25,800 | -5,500 | -9,900 | -9,800 | -17,900 | 14,300 | -3,000 | -1,300 | -12,400 | -18,500 | -2,000 | 2,000 | -8,200 |
Total non-operating income (expense) | |||||||||||||||||||||||||
7,200 | 26,600 | -33,500 | -20,300 | -13,800 | -33,400 | -6,800 | -24,500 | -16,700 | -23,200 | -10,500 | -29,600 | -26,300 | 12,400 | -19,200 | -32,300 | -34,400 | -36,700 | 1,600 | -18,300 | -21,100 | -4,200 | -35,500 | -18,700 | -4,400 | -19,100 |
Earnings from continuing operations before income taxes | |||||||||||||||||||||||||
633,900 | 419,400 | 574,400 | 361,600 | 441,000 | 456,800 | 486,400 | 346,600 | 445,000 | 334,300 | 429,500 | 322,200 | 393,200 | 356,800 | 344,000 | 215,200 | 333,000 | -727,700 | 333,500 | 232,000 | 295,800 | 232,300 | 257,000 | 63,400 | 233,000 | 189,900 |
Provision for income taxes | |||||||||||||||||||||||||
91,300 | 106,300 | 156,000 | 103,100 | 128,400 | 123,900 | 132,400 | 73,600 | 122,700 | 81,400 | 132,400 | 93,800 | 102,000 | 105,800 | 95,400 | 56,400 | 69,900 | -59,000 | 92,000 | 63,000 | 73,000 | 53,100 | 80,200 | 18,400 | 67,000 | 46,100 |
Earnings from continuing operations | |||||||||||||||||||||||||
542,600 | 313,100 | 418,400 | 258,500 | 312,600 | 332,900 | 354,000 | 273,000 | 322,300 | 252,900 | 297,100 | 228,400 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Discontinued Operations: | |||||||||||||||||||||||||
Earnings from discontinued operations, net of applicable income tax expense of $6.9 million and $0.5 million for the years ended December 31, 2013 and 2012, respectively | |||||||||||||||||||||||||
0 | 0 | 0 | 0 | 1,000 | 5,500 | 7,200 | 400 | 2,900 | -2,300 | -700 | 1,900 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Loss on sale of discontinued operation, net of applicable income tax expense (benefit) of $1.3 million and $(110.3) million for the years ended December 31, 2014 and 2013, respectively | |||||||||||||||||||||||||
-3,500 | 300 | 0 | -600 | -1,300 | -37,600 | 0 | -259,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Expected loss on sale of discontinued operations, net of applicable income tax benefit of $21.1 million and $108.3 million for the three and nine months ended September 30, 2013, respectively | |||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Discontinued operations | |||||||||||||||||||||||||
-3,500 | 300 | 0 | -600 | -300 | -32,100 | 7,200 | -258,600 | 2,900 | -2,300 | -700 | 1,900 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net earnings | |||||||||||||||||||||||||
539,100 | 313,400 | 418,400 | 257,900 | 312,300 | 300,800 | 361,200 | 14,400 | 325,200 | 250,600 | 296,400 | 230,300 | 279,700 | 251,000 | 248,600 | 158,800 | 263,100 | -668,700 | 241,500 | 169,000 | 222,800 | 179,200 | 176,800 | 45,000 | 166,000 | 143,800 |
Net earnings attributable to noncontrolling interest | |||||||||||||||||||||||||
1,900 | 900 | 1,200 | 600 | -600 | 1,000 | 1,300 | 1,900 | 1,000 | 1,200 | 1,000 | 500 | -100 | 1,200 | 2,000 | 500 | 0 | 1,800 | 1,400 | 1,100 | 1,300 | 200 | 700 | 300 | 600 | 400 |
Net earnings attributable to Allergan, Inc. | |||||||||||||||||||||||||
537,200 | 312,500 | 417,200 | 257,300 | 312,900 | 299,800 | 359,900 | 12,500 | 324,200 | 249,400 | 295,400 | 229,800 | 279,800 | 249,800 | 246,600 | 158,300 | 263,100 | -670,500 | 240,100 | 167,900 | 221,500 | 179,000 | 176,100 | 44,700 | 165,400 | 143,400 |
Earnings per share attributable to Allergan, Inc. stockholders: | |||||||||||||||||||||||||
Basic earnings per share attributable to Allergan, Inc. stockholders: | |||||||||||||||||||||||||
Continuing operations (in dollars per share) | |||||||||||||||||||||||||
1.81 | 1.05 | 1.40 | 0.87 | 1.06 | 1.12 | 1.19 | 0.91 | 1.07 | 0.84 | 0.98 | 0.75 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Discontinued operations (in dollars per share) | |||||||||||||||||||||||||
0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.11 | 0.03 | -0.87 | 0.00 | -0.01 | 0.00 | 0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net basic earnings per share attributable to Allergan, Inc. stockholders (in dollars per share) | |||||||||||||||||||||||||
1.81 | 1.05 | 1.40 | 0.86 | 1.05 | 1.01 | 1.22 | 0.04 | 1.07 | 0.83 | 0.98 | 0.76 | 0.92 | 0.82 | 0.81 | 0.52 | 0.87 | -2.21 | 0.79 | 0.55 | 0.73 | 0.59 | 0.58 | 0.15 | 0.54 | 0.47 |
Diluted earnings per share attributable to Allergan, Inc. stockholders: | |||||||||||||||||||||||||
Continuing operations (in dollars per share) | |||||||||||||||||||||||||
1.78 | 1.03 | 1.37 | 0.85 | 1.04 | 1.10 | 1.17 | 0.89 | 1.05 | 0.82 | 0.96 | 0.74 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Discontinued operations (in dollars per share) | |||||||||||||||||||||||||
-0.02 | 0.00 | 0.00 | 0.00 | -0.01 | -0.10 | 0.02 | -0.85 | 0.01 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net diluted earnings per share attributable to Allergan, Inc. stockholder (in dollars per share) | |||||||||||||||||||||||||
1.76 | 1.03 | 1.37 | 0.85 | 1.03 | 1.00 | 1.19 | 0.04 | 1.06 | 0.82 | 0.96 | 0.74 | 0.90 | 0.81 | 0.79 | 0.51 | 0.88 | -2.21 | 0.78 | 0.55 | 0.72 | 0.58 | 0.58 | 0.15 | 0.54 | 0.47 |